Iterum Therapeutics plc (ITRMF): Nasdaq/NYSE listing notice — Iterum Therapeutics receives Nasdaq delisting notice; shares to suspend Mar 5, 2026

Iterum Therapeutics plc

Received delisting determination letter on Feb 24, 2026 for failing minimum bid price of $1.00 per share.
Trading suspension on Nasdaq effective March 5, 2026 unless hearing requested before Nasdaq Hearings Panel.
Company evaluating appeal and strategic alternatives including possible wind-down or bankruptcy.
Also noncompliant with $35M minimum market value of listed securities and other listing standards.
Warns shareholders are unlikely to receive any meaningful distribution in a potential dissolution.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Iterum Therapeutics plc received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5550(b)(2), 5550(b)(1), 5550(b)(3)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5550(b)(2), 5550(b)(1), 5550(b)(3)

Exact text from the filing

February 24, 2026, Iterum Therapeutics plc (the “Company”) received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”). The Determination Letter indicated that, as a result of the Company’s previously disclosed and continued noncompliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”) for continued listing on The Nasdaq Capital Market, the Company’s ordinary shares will be scheduled for delisting and will be suspended from trading on Nasdaq effective

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Iterum Therapeutics plc filing history →

Source: SEC EDGAR

accession 0001193125-26-085646

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.